Gad Getz

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

255h-index364.1kcitations1.9kworks2.92yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(578), Cancer Immunotherapy and Biomarkers(170), Multiple Myeloma Research and Treatments(155), RNA modifications and cancer(130), Genetic factors in colorectal cancer(126)

Publications1.8k total

Learning cell dynamics with neural differential equations

1 cited

Nature Machine Intelligence·2025· 1 cited

Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

2025Open Access

Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

2025Open Access

Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

2025Open Access

Table S7 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Supplemental Figure 2 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

2025Open Access

Table S6 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Suppl Table S2 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

2025Open Access

Supplementary Fig. 6 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Supplemental Figure 6 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

2025Open Access

Supplementary Fig. 4 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Table S5 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Supplementary Fig. 3 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Table S4 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Suppl Figure S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

2025Open Access

Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

2025Open Access

Supplementary Table S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

2025Open Access

Supplementary Fig. 2 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Table S3 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

Supplementary Fig. 5 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

2025Open Access

page 1 of 88Next →

Frequent Co-authors

Stacey Gabriel(27), Michael S. Lawrence(27), Matthew Meyerson(25), Kristian Cibulskis(16), Andrew D. Cherniack(16), Gordon Saksena(15), Rameen Beroukhim(14), Juok Cho(14), Scott L. Carter(13), John A. Demchok(13), Scott Frazer(13), Nils Gehlenborg(13), David I. Heiman(13), Eric S. Lander(12), Peter W. Laird(12), Levi A. Garraway(12), Reanne Bowlby(12), Michael S. Noble(12), Wendy Winckler(11), Todd R. Golub(11)